TY  - JOUR
T1  - BRca1 and brca2 mutations in ovarian cancer
AU  - Buerkle B, Tempfer C
Y1  - 2012/01/25
N1  - 10.1001/jama.2012.8
JO  - JAMA
SP  - 359
EP  - 361
VL  - 307
IS  - 4
N2  - 
To the Editor:  Dr Yang and colleagues found significantly better progression-free survival rates in women with ovarian cancer and BRCA2 mutations compared with BRCA1 mutations or wild-type BRCA.1 In addition, they reported that BRCA2 mutations were associated with a 100% primary chemotherapy sensitivity rate compared with 82% for BRCA wild-type and 80% for BRCA1- mutated cases, suggesting an improved primary chemotherapy response in women with a BRCA2 mutation. We would like to suggest 2 alternative explanations for the observed differences in outcomes.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.8
UR  - http://dx.doi.org/10.1001/jama.2012.8
ER  -